May 13 (Reuters) - Merck said on Monday it had discontinued the arm of a late-stage study, which tested an experimental antibody-based drug with its blockbuster immunotherapy Keytruda for some patients with the most severe form of skin cancer. (Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid)